Qsam Biosciences Inc. is a developing nuclear medicine for the treatment of cancer and related diseases and conditions. The Company's technology is CycloSam, which is a clinical-staged bone targeting radiopharmaceutical developed by IsoTherapeutics Group LLC. Its IsoTherapeutics Group LLC also developed a commercial radiopharmaceutical on the market, Quadramet (Samarium-153 EDTMP), which is indicated for pain palliation. CycloSam consists of a combination of the radioactive isotope Samarium-153 and the chelant DOTMP (1,4,7,10-tetraazacyclododecanetetramethylene-phosphonic acid). Its combination forms a stable complex, which delivers a radioactive dose to sites of bone mineral turnover, such as bone cancers and tumors. CycloSam has a physical half-life of approximately 46 hours and emits both medium-energy beta particles, which produce the therapeutic effect and gamma photons that make it possible to locate the anatomical distribution. Its subsidiary is QSAM Therapeutics Inc.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)